The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Wednesday, September 01, 2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the FDA has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month ...
read more
Catalent, Inc., the leading global provider of development sciences and manufacturing platforms for medicines, including biotherapeutics; cell and ...
read more
Octapharma USA announced the FDA Office of Orphan Products Development (OOPD) has awarded seven years of marketing exclusivity for Octagam® 10% [...
read more
Lannett Company, Inc. announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally developed ...
read more
BioMarin Pharmaceutical Inc. announced that the European Commission (EC) granted marketing authorization for VOXZOGO® (vosoritide), a once daily ...
read more
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic ...
read more
Thursday, August 26, 2021
Merck announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency (...
read more
Wednesday, August 25, 2021
Eli Lilly and Company and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the ...
read more
Wednesday, August 25, 2021
Merck announced topline results from the pivotal PNEU-PED (V114-029) study evaluating the immunogenicity, safety and tolerability of VAXNEUVANCE™ (...
read more
Abveris, Inc. ("Abveris") and Abilita Bio, Inc. ("Abilita"), both privately held biotechnology companies, announce a joint research collaboration that...
read more
On August 19, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for the adjuvant treatment of patients with...
read more
Bristol Myers Squibb announced that Opdivo® (nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for intravenous use) was approved...
read more
Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca's AZD7442 achieved a statistically ...
read more
This decision is based on the recommendation of the Independent Data Monitoring Committee (IDMC), following their review of data from a pre-specified ...
read more
Regeneron Pharmaceuticals Inc. announced that the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted ...
read more